FDA Approval

FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease

Celgene Corporation

Collaboration

Jounce Therapeutics Announces Update on Strategic Collaboration with Celgene Corporation

Jounce Therapeutics

M&A

Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company

Bristol-Myers Squibb

Clinical Trials

Celgene Announces Phase III ‘AUGMENT’ Study of REVLIMID® in Combination with Rituximab (R2)

Celgene Corporation

Skyhawk Therapeutics Announces Strategic Collaboration with Celgene to Discover and Develop Novel mRNA Splicing Modifiers using Skyhawk's STAR* Technology Platform

Skyhawk

CAR-T

bluebird bio and Celgene Corporation Enter into Agreement to Co-Develop and Co-Promote Anti-BCMA CAR T Cell Therapy bb2121 in the United States

bluebird bio, Inc.

Acquisition

Celgene Completes Acquisition of Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Immunotherapy

Celgene Corporation

Acquistion

Celgene Corporation Commences Tender Offer for Juno Therapeutics, Inc.

Celgene Corporation